RxDoctor Payments Data

Walter Edmiston, MD

Cardiovascular Disease · Pasadena, CANPI 1407811128

Payments from drug & device makers

$4,725in general payments, 2019–2025

Across 238 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Pfizer$964
  • Abbott$899
  • AstraZeneca$324
  • Amgen$281
  • E.r. Squibb & Sons, L.L.C.$255
  • plus $989 from 13 others

What the payments were for

  • Food & beverage$4,712100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,725 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$142,843
Medicare patients
335
Services billed
1,902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban192$221,070
XareltoRivaroxaban75$81,768
EntrestoSacubitril/Valsartan42$45,172
MultaqDronedarone Hcl18$21,569
Praluent PenAlirocumab17$10,569
Repatha SureclickEvolocumab17$10,483
Droxidopa13$5,563
Metoprolol Succinate383$4,976
Rosuvastatin Calcium246$4,784
Valsartan74$3,394
Atorvastatin Calcium209$2,122
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide59$1,937
Potassium Chloride78$1,562
Amiodarone Hcl103$1,496
Amlodipine Besylate198$1,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$964$221,070192 claims
Johnson & JohnsonXarelto$133$81,76875 claims
NovartisEntresto$1,013$45,17242 claims
Sanofi-aventis U.S. LLCMultaq$77$21,56918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →